Authors: Croom, Katherine F.; McCormack, Paul L.

Source: Drugs, Volume 69, Number 14, 1 October 2009 , pp. 1985-2004(20)

Publisher: Adis International

Abstract:

Abstract Liraglutide (Victoza®) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus. In phase III studies, once-daily subcutaneous liraglutide improved glycaemic control compared with placebo or active comparator in adult patients with type 2 diabetes, both as monotherapy and in combination with one or two oral antidiabetic drugs such as metformin, sulfonylureas or thiazolidinediones. Liraglutide provided significantly better glycaemic control than rosiglitazone or insulin glargine in combination trials. At appropriate dosages, liraglutide was noninferior to glimepiride with respect to glycaemic control in a combination trial, but provided significantly better control than glimepiride or glibenclamide in monotherapy trials. Liraglutide improved pancreatic β-cell function, generally led to weight loss, and was associated with a low risk of hypoglycaemia. Liraglutide was generally well tolerated, with the most common adverse events being gastrointestinal events, such as nausea, which decreased over time. Thus, liraglutide is an effective treatment option for use in patients with type 2 diabetes mellitus.

Document Type: Research article

Affiliations: 1: Adis, a Wolters Kluwer Business, Auckland, New Zealand

Publication date: 2009-10-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology ,  Therapeutics & Alternative Medicine
• By this author: Croom, Katherine F. ;  McCormack, Paul L.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers